European Urology Focus · 2022 · 12 citations · 7 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDrug InteractionsPharmacovigilanceAdverse Drug Reaction ReportingAdverse Drug ReactionsAdverse EffectsAdverse Event AnalysisAdverse Event ReportingDrug Safety MonitoringAdverse Drug EventsLenvatinib TherapyMedication-related Adverse EventsOncology PharmacovigilancePembrolizumab TherapyPharmacovigilance EvidenceSerious Adverse Events
7
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +9
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Börje Ljungberg, Laurence Albigès, Yasmin Abu‐Ghanem et al. · European Urology · 2022 · 1.5K citations · Full text
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2019 · 1.2K citations · Full text
Medicine, Nephrology, Oncology +14